Psagot Investment House Ltd. acquired a new stake in Amgen, Inc. (NASDAQ:AMGN) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 28,533 shares of the medical research company’s stock, valued at approximately $5,555,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Ruggie Capital Group lifted its position in shares of Amgen by 297.1% in the fourth quarter. Ruggie Capital Group now owns 135 shares of the medical research company’s stock valued at $26,000 after buying an additional 101 shares during the last quarter. Arlington Partners LLC lifted its position in shares of Amgen by 86.7% in the fourth quarter. Arlington Partners LLC now owns 140 shares of the medical research company’s stock valued at $27,000 after buying an additional 65 shares during the last quarter. Capital Financial Planning LLC acquired a new stake in shares of Amgen in the fourth quarter valued at approximately $27,000. Massey Quick Simon & CO. LLC lifted its position in shares of Amgen by 710.5% in the fourth quarter. Massey Quick Simon & CO. LLC now owns 154 shares of the medical research company’s stock valued at $30,000 after buying an additional 135 shares during the last quarter. Finally, Next Capital Management LLC acquired a new stake in shares of Amgen in the fourth quarter valued at approximately $33,000. 79.18% of the stock is owned by institutional investors.

Several analysts recently weighed in on the company. BMO Capital Markets assumed coverage on Amgen in a report on Thursday, March 14th. They set an “outperform” rating and a $228.00 price target for the company. JPMorgan Chase & Co. reissued a “neutral” rating and set a $190.00 price target on shares of Amgen in a report on Wednesday, January 30th. Leerink Swann dropped their price target on Amgen from $200.00 to $192.00 and set a “market perform” rating for the company in a report on Wednesday, January 30th. Oppenheimer set a $224.00 price target on Amgen and gave the stock a “buy” rating in a report on Sunday, January 27th. Finally, Citigroup lifted their price target on Amgen from $204.00 to $210.00 and gave the stock a “neutral” rating in a report on Friday, January 4th. Eleven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Amgen presently has a consensus rating of “Hold” and an average price target of $209.11.

NASDAQ:AMGN opened at $177.47 on Monday. The company has a market cap of $109.31 billion, a P/E ratio of 12.32, a PEG ratio of 2.17 and a beta of 1.21. The company has a quick ratio of 2.57, a current ratio of 2.79 and a debt-to-equity ratio of 2.36. Amgen, Inc. has a 1-year low of $165.22 and a 1-year high of $210.19.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, January 29th. The medical research company reported $3.42 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.26 by $0.16. The firm had revenue of $6.23 billion during the quarter, compared to analysts’ expectations of $5.88 billion. Amgen had a return on equity of 66.74% and a net margin of 35.35%. During the same period in the previous year, the firm earned $2.89 EPS. As a group, equities research analysts forecast that Amgen, Inc. will post 13.96 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be issued a $1.45 dividend. The ex-dividend date is Thursday, May 16th. This represents a $5.80 annualized dividend and a yield of 3.27%. Amgen’s dividend payout ratio is presently 40.28%.

In other Amgen news, Director Ronald D. Sugar sold 2,000 shares of Amgen stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $188.88, for a total value of $377,760.00. Following the completion of the transaction, the director now directly owns 14,988 shares of the company’s stock, valued at approximately $2,830,933.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 6,000 shares of company stock valued at $1,144,120 over the last ninety days. Insiders own 0.27% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.watchlistnews.com/psagot-investment-house-ltd-invests-5-56-million-in-amgen-inc-amgn/2980786.html.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Recommended Story: How Short Selling Works

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.